MedTrace Logo

A Phase I Study of AK159 in Healthy Postmenopausal Women

NCT01935479 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2017-02-15

No results posted yet for this study

Summary

The objective of this study is to investigate the pharmacokinetics, safety, and tolerability of AK159 administered to healthy postmenopausal women.

Conditions

Interventions

DRUG

AK159

transdermal administration of teriparatide acetate

DRUG

MN-10-T

subcutaneous administration of teriparatide acetate

DRUG

Placebo

Placebo AK159

Sponsors & Collaborators

  • Asahi Kasei Pharma Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01935479 on ClinicalTrials.gov